|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2011-2-14
|
|
pubmed:abstractText |
In this prospective study 60 patients of median age 46 (range: 5-60 years), with acute myelogenous leukemia (AML; n = 44), acute lymphoblastic leukemia (ALL; n = 3), or myelodysplastic syndrome (MDS; n = 13) were conditioned for allogeneic hematopoietic cell transplantation with a treosulfan/fludarabine (Flu) combination. Most patients were considered at high risk for relapse or nonrelapse mortality (NRM). Patients received intravenous treosulfan, 12 g/m(2)/day (n = 5) or 14 g/m(2)/day (n = 55) on days -6 to -4, and Flu (30 mg/m(2)/day) on days -6 to -2, followed by infusion of marrow (n = 7) or peripheral blood stem cells (n = 53) from HLA-identical siblings (n = 30) or unrelated donors (n = 30). All patients engrafted. NRM was 5% at day 100, and 8% at 2 years. With a median follow-up of 22 months, the 2-year relapse-free survival (RFS) for all patients was 58% and 88% for patients without high-risk cytogenetics. The 2-year cumulative incidence of relapse was 33% (15% for patients with MDS, 34% for AML in first remission, 50% for AML or ALL beyond first remission and 63% for AML in refractory relapse). Thus, a treosulfan/Flu regimen was well tolerated and yielded encouraging survival and disease control with minimal NRM. Further trials are warranted to compare treosulfan/Flu to other widely used regimens, and to study the impact of using this regimen in more narrowly defined groups of patients.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1523-6536
|
|
pubmed:author |
pubmed-author:AppelbaumFrederick RFR,
pubmed-author:BedalovAntonioA,
pubmed-author:DeegH JoachimHJ,
pubmed-author:DoneyKristine CKC,
pubmed-author:FlowersMary EME,
pubmed-author:GuthrieKatherine AKA,
pubmed-author:HilgerRalf ARA,
pubmed-author:KovacsovicsTibor JTJ,
pubmed-author:MaziarzRichard TRT,
pubmed-author:NemecekEneida RER,
pubmed-author:PagelJohn MJM,
pubmed-author:SandersJean EJE,
pubmed-author:ScottBart LBL,
pubmed-author:SickleEileen JEJ,
pubmed-author:SorrorMohamed LML,
pubmed-author:WitherspoonRobertR,
pubmed-author:WoodBrent LBL,
pubmed-author:WoolfreyAnn EAE
|
|
pubmed:copyrightInfo |
Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
341-50
|
|
pubmed:dateRevised |
2011-9-26
|
|
pubmed:meshHeading |
pubmed-meshheading:20685259-Adolescent,
pubmed-meshheading:20685259-Adult,
pubmed-meshheading:20685259-Antineoplastic Agents,
pubmed-meshheading:20685259-Antineoplastic Agents, Alkylating,
pubmed-meshheading:20685259-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20685259-Busulfan,
pubmed-meshheading:20685259-Child,
pubmed-meshheading:20685259-Child, Preschool,
pubmed-meshheading:20685259-Female,
pubmed-meshheading:20685259-Hematologic Neoplasms,
pubmed-meshheading:20685259-Humans,
pubmed-meshheading:20685259-Leukemia, Myeloid, Acute,
pubmed-meshheading:20685259-Male,
pubmed-meshheading:20685259-Middle Aged,
pubmed-meshheading:20685259-Myelodysplastic Syndromes,
pubmed-meshheading:20685259-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:20685259-Recurrence,
pubmed-meshheading:20685259-Risk Factors,
pubmed-meshheading:20685259-Survival Analysis,
pubmed-meshheading:20685259-Transplantation Conditioning,
pubmed-meshheading:20685259-Vidarabine,
pubmed-meshheading:20685259-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
|
|
pubmed:affiliation |
Oregon Health and Science University, Portland, Oregon 97239, USA. nemeceke@ohsu.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, N.I.H., Extramural
|
